CD70: CD70 antigen
Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells.
- Drugs that act on it: 4
- Approved: 0
- In phases 1 to 3: 4
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on CD70, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
- Antibody-drug conjugate 1
- Other 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Bristol-Myers Squibb125%
- OncoVerity125%
- Pfizer125%
| Cusatuzumab | Phase 2 | OncoVerity | Antibody | InhibitorCD70 antigen inhibitor | 3 |
| Vorsetuzumab | Phase 2 | — | Antibody | Binding agentCD70 antigen binding agent | 0 |
| Vorsetuzumab mafodotin | Phase 2 | Pfizer | Antibody-drug conjugate | Binding agentCD70 antigen binding agent | 0 |
| MDX-1411 | Phase 1 | Bristol-Myers Squibb | Other | Cross-linking agentCD70 antigen cross-linking agent | 0 |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Cusatuzumab | Phase 2 | Active, not recruiting | OncoVerity, Inc. | Apr 25, 2024 |
| Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia | Cusatuzumab | Phase 1 | Active, not recruiting | OncoVerity, Inc. | Nov 5, 2019 |
| A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy | Cusatuzumab | Phase 2 | Active, not recruiting | OncoVerity, Inc. | Jul 17, 2019 |
- Severe combined immunodeficiency due to CD70 deficiency0.66
- Combined immunodeficiency0.46
- Severe combined immunodeficiency0.46
- Hematopoietic and lymphoid cell neoplasm0.29
- Non-Hodgkin lymphoma0.29
- Neurodegenerative disease0.24
- Hereditary disease0.19
- Neoplasm0.15
- Acute myeloid leukemia0.13
- Renal cell carcinoma0.12
- Nasopharyngeal carcinoma0.11
- Non-small cell lung carcinoma0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712913, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P32970, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets